ClinicalTrials.gg
TerminatedNCT04200456myOpportunITy1Updated Mar 18, 2025Results posted

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

A Phase 3 interventional study of Rozanolixizumab and Placebo in Primary Immune Thrombocytopenia, sponsored by UCB Biopharma SRL. Terminated at 29 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic Business Decision; Not a safety decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine — 1 open to participants now, 1 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Ukraine.

Enrollment
13th of 16
33 · median 54
Started
2020
with 4 others
Phase 3
12 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
3 of 16
UCB Biopharma SRL

Among the 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine, this one is the 13th largest by enrollment, is one of 5 that started in 2020, is one of 12 in phase 3, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

1 of the 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine is open now. Recruiting first, the newest first:

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Ukraine, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • ITP
  • UCB7665
  • Rozanolixizumab
  • Primary immune thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥18 years of age at the time of the Screening Visit
  • Study participant has a diagnosis of persistent (>3 months duration) or chronic (>12 months duration) primary immune thrombocytopenia (ITP) at the Screening Visit
  • Study participant has a documented intolerance or insufficient response to two or more appropriate standard of care ITP treatments prior to Screening
  • Study participants must have prior history of a response to a previous ITP therapy
  • If taking allowed drugs, study participant must be on stable doses during defined time periods prior to Baseline (Day 1)
  • Study participant has a documented history of low count (\<30×10\^9/L) prior to Screening
  • Study participant has a platelet count measurement at Screening and at Baseline (Day 1) with an average of the two \<30×10\^9/L and no single count may be >35×10\^9/L (using local laboratories)
  • Study participant has a current or history of a peripheral blood smear consistent with ITP
  • Study participants may be male or female:

    1. A male participant must agree to use during the Treatment Period and for at least 3 months after the final dose of study treatment and refrain from donating sperm during this period
    2. A female participant is eligible to participate if she is not pregnant as confirmed by a negative serum pregnancy test and not planning to get pregnant during the participation in the study, not breastfeeding, and at least one of the following conditions applies:

Not a woman of (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 3 months after the dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of arterial or venous thromboembolism (eg, stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism) within the 6 months prior to randomization or requires current anticoagulant treatment
  • Study participant has bleeding that warrants immediate adjustment (eg, menorrhagia with significant drop in )
  • Study participant has a known to any components of the study medication or any other anti-neonatal Fc receptor (FcRn) medications
  • Study participant has evidence of a secondary cause of immune thrombocytopenia (clear association with other medical conditions, eg, untreated H. pylori infection, leukemia, lymphoma, common variable immunodeficiency, systemic lupus erythematosus, thyroid disease or is drug induced), participant has a multiple immune cytopenia (eg, Evan's syndrome)
  • Study participant has a clinically relevant active infection (eg, sepsis, pneumonia, or abscess) in the opinion of the investigator, or had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of medicinal product (IMP)
  • Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current/history of nontuberculous mycobacterial infection (NTMBI)
  • Study participant has a history of a major organ transplant or hematopoietic stem cell/marrow transplant
  • Study participant has experienced intracranial bleed in the last 6 months prior to the Screening Visit
  • Study participant has a history of coagulopathy disorders other than ITP
  • Study participant with current or medical history of immunoglobulin A (IgA) deficiency, or a measurement of IgA \<50 mg/dL at the Screening Visit
  • Study participant has undergone a splenectomy in the 2 years prior to the Baseline Visit
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab

    Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.

    Drug: Rozanolixizumab

  • Placebo comparator
    Placebo

    Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.

    Other: Placebo

Interventions

  • Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.

    Also known as: UCB7665

  • OtherPlacebo

    Study participants receive placebo by subcutaneous infusion at pre-specified time points.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks

    Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50×10\^9/L, for at least 8 out of 12 weeks during the last 12 weeks were reported.

    Time frame: During the last 12 weeks (Week 13 to Week 25)

Secondary outcomes

  1. Cumulative Number of Weeks With Clinically Meaningful Platelet Response of ≥50×10^9/L Over the 24-week Treatment Period

    Total number of weeks with platelet counts ≥50×10\^9/L over the 24-week Treatment Period of the study (Week 1 to Week 25) were reported.

    Time frame: Week 1 up to Week 25

  2. Time to First Clinically Meaningful Platelet Response (CMPR) of ≥50×10^9/L: Time From Starting Treatment to Achievement of First Response of ≥50×10^9/L

    Time from starting treatment to achievement of first Clinically Meaningful Platelet Response of ≥50×10\^9/L was defined as date of first clinically meaningful response - date of first treatment + 1. Median was calculated based upon the Kaplan-Meier estimate.

    Time frame: Time from starting treatment to achievement of first response of ≥50×10^9/L (up to Week 25)

  3. Percentage of Participants With Clinically Meaningful Platelet Response of ≥50×10^9/L by Day 8

    Clinically meaningful platelet response was defined as platelet count of ≥50×10\^9/L.

    Time frame: Baseline to Day 8

  4. Percentage of Participants With Response Defined as Platelet Count ≥30*10^9/L and at Least Doubling of Baseline, at Least 2 Separate Occasions at Two Adjacent Nominal Visits at Least 7 Days Apart, and Absence of Bleeding

    Response was defined as platelet count ≥30×10\^9/L and at least doubling of baseline, at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding.

    Time frame: From Baseline during Treatment Period (up to Week 25)

  5. Time to First Rescue Therapy

    Time to first rescue therapy was defined as date of first rescue therapy use - date of first treatment + 1. Median was calculated based upon the Kaplan-Meier estimate. The probability of requiring rescue medication did not reach 0.5 so the KM median in the rozanolixizumab arm could not be estimated.

    Time frame: From Baseline to first rescue therapy (up to Week 25)

  6. Change From Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score

    The ITP-PAQ Version 1 is a 44 item disease-specific Health-Related Quality of Life questionnaire developed for use in adults with chronic ITP. It includes 10 scales, Four of the scales measure physical health: Symptoms (6 items), Bother (3 items), Fatigue (4 items), and Activity (2 items). Two of the scales measure emotional health: Fear (5 items) and Psychological (5 items) Health. The remaining four scales measure other aspects of quality of life (QOL): Work QOL (4 items), Social QOL (4 items), Women's Reproductive QOL (6 items) and Overall QOL (5 items). Each item is rated on a Likert-type scale containing 4 to 7 responses. All item scores are transformed to a 0 to 100 continuum and are weighted equally to derive individual scale scores and the total score (0-100) is calculated as per the formula: Sum of item scores within the scale/raw sum range\*100. Higher scores indicate better health status.

    Time frame: From Baseline during Treatment Period (up to Week 25)

  7. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

    Time frame: From Baseline to end of Safety Follow-Up Period (up to Week 31)

  8. Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (ie, Study Discontinuation)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

    Time frame: From Baseline to end of Safety Follow-Up Period (up to Week 31)

07

Results

Posted Aug 8, 2023

Participant flow

The study started to enroll study participants in Jan 2020 and terminated on April 2022.

Participant flow — Overall Study
MilestonePlaceboRozanolixizumab
Started1221
Completed915
Not completed36
Withdrew: Physician decision01
Withdrew: Withdrawal by subject22
Withdrew: Lack of efficacy11
Withdrew: Adverse event, non-fatal01
Withdrew: Administration of rescue and concern about imp01

Outcome measures

PrimaryPercentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks

Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50×10\^9/L, for at least 8 out of 12 weeks during the last 12 weeks were reported.

Time frame:
During the last 12 weeks (Week 13 to Week 25)
Reported as:
Number · Percentage of participants
Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks
Percentage of participantsPlaceboRozanolixizumab
Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks019.0
SecondaryCumulative Number of Weeks With Clinically Meaningful Platelet Response of ≥50×10^9/L Over the 24-week Treatment Period

Total number of weeks with platelet counts ≥50×10\^9/L over the 24-week Treatment Period of the study (Week 1 to Week 25) were reported.

Time frame:
Week 1 up to Week 25
Reported as:
Median · Weeks
Cumulative Number of Weeks With Clinically Meaningful Platelet Response of ≥50×10^9/L Over the 24-week Treatment Period
WeeksPlaceboRozanolixizumab
Cumulative Number of Weeks With Clinically Meaningful Platelet Response of ≥50×10^9/L Over the 24-week Treatment Period0.0 (0 to 7)3.0 (0 to 24)
SecondaryTime to First Clinically Meaningful Platelet Response (CMPR) of ≥50×10^9/L: Time From Starting Treatment to Achievement of First Response of ≥50×10^9/L

Time from starting treatment to achievement of first Clinically Meaningful Platelet Response of ≥50×10\^9/L was defined as date of first clinically meaningful response - date of first treatment + 1. Median was calculated based upon the Kaplan-Meier estimate.

Time frame:
Time from starting treatment to achievement of first response of ≥50×10^9/L (up to Week 25)
Reported as:
Median · days
Time to First Clinically Meaningful Platelet Response (CMPR) of ≥50×10^9/L: Time From Starting Treatment to Achievement of First Response of ≥50×10^9/L
daysPlaceboRozanolixizumab
Time to First Clinically Meaningful Platelet Response (CMPR) of ≥50×10^9/L: Time From Starting Treatment to Achievement of First Response of ≥50×10^9/L44.0 (6.0 to NA)8.0 (6.0 to NA)
SecondaryPercentage of Participants With Clinically Meaningful Platelet Response of ≥50×10^9/L by Day 8

Clinically meaningful platelet response was defined as platelet count of ≥50×10\^9/L.

Time frame:
Baseline to Day 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Meaningful Platelet Response of ≥50×10^9/L by Day 8
Percentage of participantsPlaceboRozanolixizumab
Percentage of Participants With Clinically Meaningful Platelet Response of ≥50×10^9/L by Day 816.752.4
SecondaryPercentage of Participants With Response Defined as Platelet Count ≥30*10^9/L and at Least Doubling of Baseline, at Least 2 Separate Occasions at Two Adjacent Nominal Visits at Least 7 Days Apart, and Absence of Bleeding

Response was defined as platelet count ≥30×10\^9/L and at least doubling of baseline, at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding.

Time frame:
From Baseline during Treatment Period (up to Week 25)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined as Platelet Count ≥30*10^9/L and at Least Doubling of Baseline, at Least 2 Separate Occasions at Two Adjacent Nominal Visits at Least 7 Days Apart, and Absence of Bleeding
Percentage of participantsPlaceboRozanolixizumab
Percentage of Participants With Response Defined as Platelet Count ≥30*10^9/L and at Least Doubling of Baseline, at Least 2 Separate Occasions at Two Adjacent Nominal Visits at Least 7 Days Apart, and Absence of Bleeding8.333.3
SecondaryTime to First Rescue Therapy

Time to first rescue therapy was defined as date of first rescue therapy use - date of first treatment + 1. Median was calculated based upon the Kaplan-Meier estimate. The probability of requiring rescue medication did not reach 0.5 so the KM median in the rozanolixizumab arm could not be estimated.

Time frame:
From Baseline to first rescue therapy (up to Week 25)
Reported as:
Median · Days
Time to First Rescue Therapy
DaysPlaceboRozanolixizumab
Time to First Rescue Therapy34.5 (4.0 to NA)NA (23.0 to NA)
SecondaryChange From Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score

The ITP-PAQ Version 1 is a 44 item disease-specific Health-Related Quality of Life questionnaire developed for use in adults with chronic ITP. It includes 10 scales, Four of the scales measure physical health: Symptoms (6 items), Bother (3 items), Fatigue (4 items), and Activity (2 items). Two of the scales measure emotional health: Fear (5 items) and Psychological (5 items) Health. The remaining four scales measure other aspects of quality of life (QOL): Work QOL (4 items), Social QOL (4 items), Women's Reproductive QOL (6 items) and Overall QOL (5 items). Each item is rated on a Likert-type scale containing 4 to 7 responses. All item scores are transformed to a 0 to 100 continuum and are weighted equally to derive individual scale scores and the total score (0-100) is calculated as per the formula: Sum of item scores within the scale/raw sum range\*100. Higher scores indicate better health status.

Time frame:
From Baseline during Treatment Period (up to Week 25)
Reported as:
Mean · units on a scale
Change From Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score
units on a scalePlaceboRozanolixizumab
Change From Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score6.9 ± 13.85.5 ± 9.2
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

Time frame:
From Baseline to end of Safety Follow-Up Period (up to Week 31)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Percentage of participantsPlaceboRozanolixizumab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)75.085.7
SecondaryPercentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (ie, Study Discontinuation)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 8 weeks (56 days) after the final dose.

Time frame:
From Baseline to end of Safety Follow-Up Period (up to Week 31)
Reported as:
Number · Percentage of participants
Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (ie, Study Discontinuation)
Percentage of participantsPlaceboRozanolixizumab
Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (ie, Study Discontinuation)04.8

Adverse events

Collected over From Baseline to end of Safety Follow-Up Period (up to Week 31). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/12 (0%)1/12 (8.3%)9/12 (75%)
Rozanolixizumab0/21 (0%)2/21 (9.5%)16/21 (76.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboRozanolixizumab
HaemorrhageVascular disorders1/120/21
Immune thrombocytopeniaBlood and lymphatic system disorders0/121/21
UrethritisInfections and infestations0/121/21
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboRozanolixizumab
HeadacheNervous system disorders5/1214/21
PyrexiaGeneral disorders0/129/21
NauseaGastrointestinal disorders1/125/21
VomitingGastrointestinal disorders0/124/21
AnaemiaBlood and lymphatic system disorders2/123/21
DiarrhoeaGastrointestinal disorders2/122/21
Seasonal allergyImmune system disorders2/120/21
COVID-19Infections and infestations2/121/21
RhinitisInfections and infestations0/122/21
Body temperature increasedInvestigations0/122/21

Baseline characteristics

Baseline Characteristics refer to Randomized Set which consisted of all enrolled study participants who were randomized.

Age, Categorical
Age, Categorical(Participants)PlaceboRozanolixizumabTotal
<=18 years011
Between 18 and 65 years101828
>=65 years224
Age, Continuous
Age, Continuous(years)PlaceboRozanolixizumabTotal
Mean51.4 ± 15.941.4 ± 12.845.1 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRozanolixizumabTotal
Female111223
Male1910
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRozanolixizumabTotal
Asian145
White111627
Missing011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRozanolixizumabTotal
Hispanic or Latino011
Not Hispanic or Latino122032
Platelet count
Platelet count(cells*10^9/L)PlaceboRozanolixizumabTotal
Mean17.2 ± 11.317.0 ± 9.417.1 ± 9.9
08

Study locations

29 sites
  • Tp0003 50244
    Seattle, Washington 98104, United States
  • Tp0003 40188
    Sofia, Bulgaria
  • Tp0003 40197
    Amiens, France
  • Tp0003 40196
    Pessac Cedex, France
  • Tp0003 20050
    Tbilisi, Georgia
  • Tp0003 40558
    Thessaloniki, Greece
  • Tp0003 40202
    Győr, Hungary
  • Tp0003 40178
    Nyíregyháza, Hungary
  • Tp0003 40204
    Pécs, Hungary
  • Tp0003 40208
    Firenze, Italy
  • Tp0003 20030
    Chuo-ku, Japan
  • Tp0003 20039
    Iruma-gun, Japan
  • Tp0003 20159
    Shibuya-ku, Japan
  • Tp0003 20218
    Daegu, Korea, Republic of
  • Tp0003 20207
    Seoul, Korea, Republic of
  • Tp0003 20051
    Chisinau, Moldova, Republic of
  • Tp0003 40218
    Gdansk, Poland
  • Tp0003 40221
    Lodz, Poland
  • Tp0003 40222
    Skorzewo, Poland
  • Tp0003 40226
    Bucharest, Romania
  • Tp0003 40225
    Bucuresti, Romania
  • Tp0003 20055
    Sankt-peterburg, Russian Federation
  • Tp0003 20099
    Taipei, Taiwan
  • Tp0003 20060
    Dnipropetrovsk, Ukraine
  • Tp0003 20062
    Ivano-frankivsk, Ukraine
  • Tp0003 20063
    Kyiv, Ukraine
  • Tp0003 20100
    Zaporizhzhia, Ukraine
  • Tp0003 40238
    London, United Kingdom
  • Tp0003 40234
    Plymouth, United Kingdom
09

References and documents

Publications

  • Cooper N, Bussel JB, Kazmierczak M, Miyakawa Y, Cluck S, Lledo Garcia R, Haier B, Lavrov A, Singh P, Snipes R, Kuter DJ. Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension. Br J Haematol. 2025 Feb;206(2):675-688. doi: 10.1111/bjh.19858. Epub 2024 Nov 18. PubMed 39552477 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2022, 25 months.

Results were first posted in Aug 2023, 1 year 4 months after primary completion. A results delay was requested in Dec 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2019
First posted
Dec 16, 2019
StartActual
Jan 31, 2020
Primary completionActual
Mar 21, 2022
CompletionActual
Apr 27, 2022
Results delay requested
Dec 19, 2022
Results first posted
Aug 8, 2023
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04200456
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 16, 2019
Start date
Jan 31, 2020
Primary completion
Mar 21, 2022
Completion
Apr 27, 2022
Results posted
Aug 8, 2023
Last update
Mar 18, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion